3-Methyl-6-Nitroindazole CAS 6494-19-5 Puritas >98.0% (HPLC)

Description:

Nomen chemicum: 3-Methyl-6-Nitroindazole

CAS: 6494-19-5

Puritas: >98.0% (HPLC)

Lux Yellow ad Dark Yellow ad Brown pulveris ad Crystal

High Quality, Commercial Production

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Shanghai Ruifu Chemical Co., Ltd. is the leading supplier of 3-Methyl-6-Nitroindazole (CAS: 6494-19-5) with high quality. We can provide COA, worldwide delivery, small and bulk quantities available. If you are interested in this product, please send detailed information includes CAS number, product name, quantity to us. Please contact: alvin@ruifuchem.com

Chemical Properties:

Nomen chemicum	3-Methyl-6-Nitroindazole
Synonyma	3-Methyl-6-Nitro-1H-Indozole;6-Nitro-3-Methylindazole
CAS Number	6494-19-5
CATTUS Number	RF2682
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C8H7N3O2
M. Pondus	177.16
Liquescens punctum	184.0 ad 188.0℃
Ferveret	384.9±22.0℃
Density	1.437
Solubilitas	Chloroform (paulo), Methanol (paulo)
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Lux Yellow ad Dark Yellow ad Brown pulveris ad Crystal
Puritas / Analysis Methodus	>98.0% (HPLC)
Liquescens punctum	184.0 ad 188.0℃
Damnum in Siccatio	<1.00%
Totalis immunditias	<2.00%
Infrared Imaginis	Conformat ut Structure
Proton NMR Spectrum	Conformat ut Structure
Test Standard	Enterprise Standard
Consuetudinem	Pharmaceutical Medium;Pazopanib Hydrochloride media

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

Satis capacitas: sufficientes facilities et technici

Professional Service: One stop acquireing service

Altera Package: Custom sarcina ac titulus praesto

Ieiunium Delivery: Si intra stirpem, tres dies partus praestatur

Supple firmum: Esse rationabile stirpe

Technical Support: Technology solution praesto

Custom Synthesis Service: Range from P. to kilos

High Quality: Constitutus ratio completa qualitas certitudinis

FAQ:

Quam mercari?Please contact: sales@ruifuchem.com or alvin@ruifuchem.com

15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.

Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Russiam, Coream, Iaponicam, Australiam etc.

Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.

Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.

Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.

Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.

MOQ?Nec MOQ.Parvus ordo placet.

Tempus adferendi? Si intus prosapia, tres dies partus praestatur.

Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.

Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.

Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.

Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

Applicatio:

3-Methyl-6-Nitroindazole (CAS: 6494-19-5) adhibetur ut pharmaceuticum intermedium.Intermedium adhiberi potest ex Hydrochloride Pazopanib (CAS: 635702-64-6).Hydrochloride Pazopanib per GlaxoSmithKline investigetur et evolvitur, est nova oralis vascularis generationis inhibitoris quae pertinax tumor superstes et novus venas generationis incrementum necessarius impedire potest.Nisl vascular incrementum endotheliale factor receptor (VEGFR), operatur inhibendo angiogenesis copia sanguinis tumoris.Apta est ad carcinoma renum provectis (inventus cellae cancri in tubulis renum), sarcoma mollis textus (STS), cancri ovarii epithelialis et non parvae cellulae pulmonis cancri (NSCLC) curationem.US Cibus et Drug Administration (FDA) die 19 Octobris approbavit, MMIX quod Hydrochloridum Pazopanib (nomen Votrient) recensetur, sextum curationem medicamentorum renis ab anno 2005 probatam.